Xencor, Inc. (XNCR) Downgraded to “Sell” at BidaskClub
Xencor, Inc. (NASDAQ:XNCR) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Monday.
Other analysts have also recently issued reports about the company. Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research note on Tuesday, August 8th. Zacks Investment Research cut Xencor from a “buy” rating to a “hold” rating in a research note on Saturday, April 29th. Finally, Wedbush reiterated an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a research note on Friday, June 16th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $29.33.
Shares of Xencor (NASDAQ:XNCR) traded up 1.17% on Monday, hitting $21.63. The stock had a trading volume of 229,184 shares. The firm’s market cap is $1.02 billion. Xencor has a 12-month low of $18.45 and a 12-month high of $29.38. The stock has a 50 day moving average of $22.61 and a 200 day moving average of $23.06.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.10. The business had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. Equities analysts predict that Xencor will post ($1.17) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Xencor, Inc. (XNCR) Downgraded to “Sell” at BidaskClub” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.watchlistnews.com/xencor-inc-xncr-downgraded-to-sell-at-bidaskclub/1488256.html.
In other Xencor news, major shareholder John S. Stafford III purchased 1,500 shares of the business’s stock in a transaction on Friday, June 16th. The shares were bought at an average cost of $19.67 per share, for a total transaction of $29,505.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III purchased 6,000 shares of the business’s stock in a transaction on Wednesday, June 28th. The stock was acquired at an average price of $19.94 per share, for a total transaction of $119,640.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 34,500 shares of company stock worth $719,655 and sold 34,766 shares worth $739,408. 4.14% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. Equitec Specialists LLC acquired a new stake in Xencor during the second quarter worth $116,000. SG Americas Securities LLC boosted its stake in Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 3,252 shares in the last quarter. Legal & General Group Plc boosted its stake in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares in the last quarter. Airain ltd acquired a new stake in Xencor during the first quarter worth $213,000. Finally, Citadel Advisors LLC acquired a new stake in Xencor during the second quarter worth $224,000. Institutional investors own 73.53% of the company’s stock.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.